RxDoctor Payments Data

Anna Willis, PA

Physician Assistant · Lone Tree, CONPI 1952652729

Payments from drug & device makers

$1,305in general payments, 2019–2025

Across 25 payments — averaging $52.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Dendreon Pharmaceuticals LLC$224
  • Progenics Pharmaceuticals, Inc.$195
  • Johnson & Johnson$180
  • Bayer$125
  • Urogen Pharma, Inc.$125
  • Sumitomo Pharma America, Inc.$122
  • plus $333 from 9 others

What the payments were for

  • Food & beverage$1,23795%
  • Education$685%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,305 in reported general payments places this provider in the 75th percentile of 2,849 physician assistant providers in Colorado.

See all physician assistant providers in Colorado

Medicare billing

Part B allowed, 2024
$82,345
Medicare patients
340
Services billed
1,376

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron34$33,373
MyrbetriqMirabegron44$29,252
Testosterone50$5,156
Tamsulosin Hcl240$3,249
Potassium Citrate ErPotassium Citrate29$2,383
Finasteride136$2,134
Estradiol16$1,256
Testosterone Cypionate54$1,037
Alfuzosin Hcl ErAlfuzosin Hcl44$918
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav79$725
Tadalafil16$573
Allopurinol45$498
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim54$358
Ciprofloxacin Hcl45$314
Oxybutynin Chloride37$207

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$122$33,37334 claims
Astellas Pharma US IncMyrbetriq$94$29,25244 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,849 physician assistant providers in Colorado.

Other physician assistant in Lone Tree

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →